Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration

Pharmacology

Volumn 88, Issue 1-2, 2011, Pages 44-49

  Sawyer, E K ^a   Howell, L L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoxetine; Nonhuman primate; Norfluoxetine; Pharmacokinetics; Selective serotonin reuptake inhibitors

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; MACACA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; FEMALE; FLUOXETINE; HUMANS; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; MICE; MODELS, ANIMAL; RATS; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY; TIME FACTORS;

EID: 79960208360     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000329417     Document Type: Article

References (18)

1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 1995; 57: 411-441.
2. Clark RN, Ashby CR Jr, Dewey SL, Ramachandran PV, Strecker RE: Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 1996; 23: 125-131. (Pubitemid 26230559)
3. Thompson C: Onset of action of antidepressants: Results of different analyses. Hum Psychopharmacol 2002; 17(suppl 1):S27-S32. (Pubitemid 34678888)
4. Vaswani M, Linda FK, Ramesh S: Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102. (Pubitemid 36131110)
5. Hiemke C, Hartter S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28.
6. Preskorn SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(suppl 1):1-21. (Pubitemid 27107715)
7. Qu Y, Aluisio L, Lord B, Boggs J, Hoey K, Mazur C, Lovenberg T: Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. Pharmacol Biochem Behavior 2009; 92: 469-473.
8. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469. (Pubitemid 26415952)
9. Amsterdam JD, Hornig-Rohan JF, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, Beasley CM Jr: Fluoxetine and norfluoxetine plasma levels in major depression. Biological Psychiatry 1995; 37: 606.
10. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Muller-Oerlinghausen B, Rao ML, Riederer P, Zernig G: The agnp-tdm expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265. (Pubitemid 39587052)
11. Brunswick DJ, Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley CM Jr: Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. J Affect Disord 2002; 68: 243-249. (Pubitemid 34628331)
12. Reis M, Aamo T, Spigset O, Ahlner J: Serum concentrations of antidepressant drugs in a naturalistic setting: Compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009; 31: 42-56.
13. Fontenot MB, Musso MW, McFatter RM, Anderson GM: Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques ( Macaca mulatta ). J Am Assoc Lab Anim Sci 2009; 48: 176-184.
14. Ritchie J, Glover B, Ramsey C, Scott-Harrell P: A routine uplc-lc/ms/ms assay for the newer antidepressants. Ther Drug Monit 2009; 31: 646.
15. Altamura AC, Moro AR, Percudani M: Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214. (Pubitemid 24081625)
16. Hodes GE, Hill-Smith TE, Suckow RF, Cooper TB, Lucki I: Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 2010; 332: 266-273.
17. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome p450 2b (cyp2b) in rat liver: An in vitro and in vivo study. Pharmacol Rep 2008; 60: 957-965.
18. Daniel WA, Haduch A, Syrek M, Boksa J: Direct and indirect interactions between antidepressant drugs and cyp2c6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 2006; 16: 580-587. (Pubitemid 44716661)